About Xilis
Informed Choices. Better Outcomes.
Developed by world-class scientists from the U.S. and Europe, Xilis’ MicroOrganoSphereTM (MOS) technology and Precision Oncology Platform is transforming treatment choices in the clinic and bringing novel therapeutics to patients.

Technology
Xilis is developing next-generation technologies to guide precision therapy for cancer patients and accelerate drug discovery and development. MOSTM are microscale tumors that retain structure, genetic alterations, gene expression, immune microenvironment, and histopathology from individual patients. Our MOS platform enables rapid diagnostics for personalized therapy prioritization by predicting patient response, and scalable patient-derived models for high-throughput and immuno-oncology drug discovery.

Precision Oncology
Xilis’ Precision Oncology Platform enables clinicians to make timely treatment decisions by predicting patient treatment response and guiding optimal therapeutic options. The Xilis Precision Oncology Platform and Xilis Response ScoreTM can guide prioritized treatment decisions for oncologists and ensure patients get the right drug at the right time.

Drug Development
The MOSTM technology is transforming cancer drug development by providing an end-to-end patient centric solution. Our breakthrough platform provides cost-effective, high-throughput drug candidate screening, pre-clinical assessment of immuno-oncology drugs, personalized assays to determine patient eligibility for clinical trials, and companion diagnostics to guide patients to newly developed treatments.

News
-
Biotech Startups Use Models of Human Organs for Drug Discovery
April 26, 2023 , Industry News
-
A novel and rapid patient-derived organoid breast cancer platform for precision medicine
April 21, 2023 , Abstacts and Posters
-
Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS)TM enables correlation of targeted therapy combination response with clinical outcomes
April 21, 2023 , Abstacts and Posters
-
Patient-derived MicroOrganoSpheres (MOS)TM enable precision clinical decision-making for multiple myeloma patients
April 20, 2023 , Abstacts and Posters
-
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development
February 15, 2023 , Press Releases
-
Feasibility of establishing and drug screening patient-derived rectal organoid models from pretreatment rectal cancer biopsies
January 19, 2023 , Abstacts and Posters
-
Xilis Announces Formation of its Scientific Advisory Board
December 15, 2022 , News
-
A path to translation: How 3D patient tumor avatars enable next generation precision oncology
October 20, 2022 , Publication
-
Rapid tissue prototyping with micro-organospheres
September 13, 2022 , Publication
-
Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million
July 13, 2022 , Press Releases